Treatment of insulin dependent diabetes mellitus with intravascular transplantation of pancreatic islet cells without immunosuppressive therapy

Av, Prochorov; Si, Tretjak; Va, Goranov; Aa, Glinnik; Mv, Goltsev

doi:10.2478/v10039-008-0045-5

Cited by 38 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The islet seeded NGF and Gelitaspon discs are brought into close proximity immediately adjacent to a rapidly expanding rich blood supply so that a pre-vascularisation period is not required. This is supported by a recent clinical study by Prochorov et al [2008], in which transplantation of encapsulated rabbit islets ( 1 6,000 IEQs) into a vascular lumen reduced insulin dependence in 73.7% of the patients within 2 years.…”

Section: Discussionsupporting

confidence: 58%

“…These include the peritoneum, the epididymal fat pad, muscle, spleen, the mammary fat pad, the omentum and renal capsule [Balamurugan et al, 2006]. More recently, intravascular transplantation of encapsulated islets has been trialed as a possible treatment for T1D, with promising results [Prochorov et al, 2008]. Our preliminary studies in this field have used a tissue-engineering chamber model based on the superficial epigastric pedicle using bFGF-supplemented Matrigel TM as the carrier matrix for the transplanted islets.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pancreatic Islet Transplantation Using Vascularised Chambers Containing Nerve Growth Factor Ameliorates Hyperglycaemia in Diabetic Mice

Hussey¹,

Winardi²,

Wilson³

et al. 2010

Cells Tissues Organs

View full text Add to dashboard Cite

Intraportal islet transplantation has shown initial promise for the treatment of type 1 diabetes. However, the portal vein site is associated with complications such as thrombosis and hepatic steatosis, leading to transplant failure. The aims of this study were to (1) test the feasibility of an alternative islet transplantation method that utilises a FDA-approved gelatin sponge as a novel islet carrier and (2) assess if exogenous addition of nerve growth factor (NGF) has any additional beneficial effects on graft performance in diabetic mice. Mice were rendered diabetic by a single intraperitoneal injection of streptozotocin. Five hundred syngeneic islets were seeded onto a Gelitaspon® disc in the presence or absence of NGF, and placed into a silicone chamber surrounding the femoral neurovascular pedicle. Islet function was assessed by weekly monitoring of blood glucose levels and an intraperitoneal glucose tolerance test performed at the end of the study. Chambers were harvested for further histological analysis. Four of five mice transplanted with islets seeded onto Gelitaspon with NGF showed a significant reduction in blood glucose levels by 4 weeks after transplantation, and demonstrated a response similar to non-diabetic mice when tested with an intraperitoneal glucose tolerance test. Chamber tissue from this group contained islets with insulin-producing β cells adjacent to the vascular pedicle. Islets seeded onto Gelitaspon with NGF and sited on femoral vessels using a tissue-engineering chamber offer an alternative method for islet transplantation in diabetic mice. This may have potential as a method for clinical islet transplantation.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Introductionmentioning

confidence: 99%

Pancreatic Islet Transplantation Using Vascularised Chambers Containing Nerve Growth Factor Ameliorates Hyperglycaemia in Diabetic Mice

Hussey¹,

Winardi²,

Wilson³

et al. 2010

Cells Tissues Organs

View full text Add to dashboard Cite

show abstract

“…In addition, the umbilical vein can be approached both during open surgery for total pancreatectomy and islet autotransplant and also under local anaesthetic above the umbilicus for allograft patients that require repeated transplants [7]. This method would extend the indications for this methodology of infusion in situations where pancreatectomy is not required including xenogenic islets [19] or stem cells transplantations [20,21] for the treatment of type 1 or type 2 diabetes. Furthermore, the recanalised umbilical vein provides excellent access for postoperative venous sampling, pharmacological manipulations and portal pressure measurements as it can be safely exteriorised for at least 5 days following surgery.…”

Section: Discussionmentioning

confidence: 99%

Use of the Recanalised Umbilical Vein for Islet Autotransplantation following Total Pancreatectomy

et al. 2011

View full text Add to dashboard Cite

“…Thus, research on intravascular devices has remained on hold since the 1990s (Petruzzo et al, 1991;Maki et al, 1996;Maki and Monaco, 1997). But in 2008, Prochorov et al (2008) conducted an intravascular implantation of fetal rabbit islets (>6000 IEQs/kg) contained in nylon microporous macrocapsules into the arterial-venous fistulas of T1DM patients without immunosuppression. All recipients were given the current standard antithrombotic therapy.…”

Section: Intravascular Devicesmentioning

confidence: 99%

Treatment of diabetes with encapsulated pig islets: an update on current developments

Zhu

Liu

et al. 2015

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:The potential use of allogeneic islet transplantation in curing type 1 diabetes mellitus has been adequately demonstrated, but its large-scale application is limited by the short supply of donor islets and the need for sustained and heavy immunosuppressive therapy. Encapsulation of pig islets was therefore suggested with a view to providing a possible alternative source of islet grafts and avoiding chronic immunosuppression and associated adverse or toxic effects. Nevertheless, several vital elements should be taken into account before this therapy becomes a clinical reality, including cell sources, encapsulation approaches, and implantation sites. This paper provides a comprehensive review of xenotransplantation of encapsulated pig islets for the treatment of type 1 diabetes mellitus, including current research findings and suggestions for future studies.

show abstract

Treatment of insulin dependent diabetes mellitus with intravascular transplantation of pancreatic islet cells without immunosuppressive therapy

Cited by 38 publications

References 13 publications

Pancreatic Islet Transplantation Using Vascularised Chambers Containing Nerve Growth Factor Ameliorates Hyperglycaemia in Diabetic Mice

Pancreatic Islet Transplantation Using Vascularised Chambers Containing Nerve Growth Factor Ameliorates Hyperglycaemia in Diabetic Mice

Use of the Recanalised Umbilical Vein for Islet Autotransplantation following Total Pancreatectomy

Treatment of diabetes with encapsulated pig islets: an update on current developments

Contact Info

Product

Resources

About